Search Results

• • 311 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• IL-11 signaling as a therapeutic target for cancer

  Authors:Tracy L Putoczki and Matthias ErnstFrom:Immunotherapy (Vol. 7, Issue 4) Peer-Reviewed

  Apr. 201510,515 words Report 2440LAuthor(s): Tracy L Putoczki aff1 , Matthias Ernst [*] aff1 aff2 Keywords: cancer; GP130; IL-11; IL-6; inflammation; STAT3; therapy Background IL-11 is a member of the IL-6 family of cytokines, which includes...

• Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus

  Authors:J. Hughes, P. Wang, G. Alusi, H. Shi, Y. Chu, J. Wang, et al.From:Gene Therapy (Vol. 22, Issue 6) Peer-Reviewed

  June 20156,362 words Report 1880LVaccinia virus (VV) has many attractive characteristics as a potential cancer therapeutic. There are several strains of VV. The nonvaccine strain Western Reserve VV with deletion of both the thymidine kinase and the...

• De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer

  Authors:Adela Madrid-Paredes, Marisa Canadas-Garre, Antonio Sanchez-Pozo, and Miguel Angel Calleja-HernandezFrom:Pharmacogenomics (Vol. 16, Issue 12) Peer-Reviewed

  Aug. 201510,298 words Report 2360LAuthor(s): Adela Madrid-Paredes aff1 aff2 , Marisa Cañadas-Garre [*] aff1 , Antonio Sánchez-Pozo aff2 , Miguel Ángel Calleja-Hernández aff1 aff3 Keywords: breast cancer; HER2-targeted therapies; lapatinib;...

• Synergism between NF-kappa B inhibitor, celastrol, and XIAP inhibitor, embelin, in an acute myeloid leukemia cell line, HL-60

  Authors:Yaghub Pazhang, Hossein Jaliani, Mehdi Imani, and Hassan DariushnejadFrom:Journal of Cancer Research and Therapeutics (Vol. 12, Issue 1) Peer-Reviewed

  January-March 20163,040 words Report 1600LByline: Yaghub. Pazhang, Hossein. Jaliani, Mehdi. Imani, Hassan. Dariushnejad Aim of Study: Embelin and celastrol, inhibitors of XIAP and NF-?B proteins respectively, have been derived from natural sources and shown...

• New agents for the treatment of advanced bladder cancer

  Authors:Philippa J. Cheetham and Daniel P. PetrylakFrom:Oncology (Vol. 30, Issue 6) Peer-Reviewed

  June 20167,317 words Report 1610LDespite recent advances in the management of a wide variety of solid tumors, the outcomes for patients with metastatic urothelial carcinoma (MUC) remain extremely poor. Cisplatin-based combination chemotherapy remains...

• Low-grade serous carcinoma of the ovary

  Author:Rachel N. GrishamFrom:Oncology (Vol. 30, Issue 7) Peer-Reviewed

  July 20161,769 words Report 1950LIntroduction The World Health Organization classification system of ovarian cancer, published in 2014 by Kurman et al, eliminated the older practice of grading serous tumors on a continuum (grade 1, 2, or 3) and...

• Improving treatment of liver metastases by targeting nonangiogenic mechanisms

  Authors:Kyrre E Emblem and Rakesh K JainFrom:Nature Medicine (Vol. 22, Issue 11) Peer-Reviewed

  Nov. 20161,499 words Report 1570LAuthor(s): Kyrre E Emblem (corresponding author) [1]; Rakesh K Jain [2] Since 2004, a dozen drugs that target either VEGFA or its receptors have been approved for the treatment of ten different malignancies. In...

• Chaperone-mediated autophagy and mitochondrial homeostasis in Parkinson's disease

  Authors:Ruixin Yang, Guodong Gao, Zixu Mao, and Qian YangFrom:Parkinson's DiseasePeer-Reviewed

  Annual 20166,357 words Report 1390LParkinson's disease (PD), a complex neurodegenerative disorder, is pathologically characterized by the formation of Lewy bodies and loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). Mitochondrial...

• Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy

  Authors:D. Young, D.M. Fong, P.A. Lawlor, A. Wu, A. Mouravlev, M. McRae, et al.From:Gene Therapy (Vol. 21, Issue 12) Peer-Reviewed

  Dec. 20149,766 words Report 1900LAstrocytes are an attractive cell target for gene therapy, but the validation of new therapeutic candidates is needed. We determined whether adeno-associated viral (AAV) vector-mediated overexpression of glutamine...

• Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies

  Authors:Sabrina Rizzolio, Gabriella Cagnoni, Chiara Battistini, Stefano Bonelli, Claudio Isella, Jo A. Van Ginderachter, et al.From:Journal of Clinical Investigation (Vol. 128, Issue 9) Peer-Reviewed

  Sept. 201811,142 words Report 1470LCancer cell dependence on activated oncogenes is therapeutically targeted, but acquired resistance is virtually unavoidable. Here we show that the treatment of addicted melanoma cells with BRAF inhibitors, and of breast...

• Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies

  Authors:Gaetano Bertino, Shirin Demma, Annalisa Ardiri, Maria Proiti, Salvatore Gruttadauria, Adriana Toro, et al.From:BioMed Research InternationalPeer-Reviewed

  Annual 201412,002 words Report 1430LBackground. Hepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying...

• Oxidized CaMKII and 0-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms.

  Authors:Olurotimi O. Mesubi, Adam G. Rokita, Neha Abrol, Yuejin Wu, Biyi Chen, Qinchuan Wang, et al.From:Journal of Clinical Investigation (Vol. 131, Issue 2) Peer-Reviewed

  Jan. 15, 20218,469 words Report 1420LDiabetes mellitus (DM) and atrial fibrillation (AF) are major unsolved public health problems, and diabetes is an independent risk factor for AF. However, the mechanism(s) underlying this clinical association is unknown....

• The use of Gc protein-derived macrophage activating factor for management of thyroid cancer

  Authors:Kamon Chaiyasit, Inui Toshio, and Viroj WiwanitkitFrom:Journal of Cancer Research and Therapeutics (Vol. 11, Issue 4) Peer-Reviewed

  October-December 2015344 words Brief article, Lette... 1490LByline: Kamon. Chaiyasit, Inui. Toshio, Viroj. Wiwanitkit Sir, The use of Gc protein-derived macrophage activating factor (GcMAF) for management of cancer is interesting. Basically, Gcprotein is an important...

• New strategies for evaluation and analysis of SELEX experiments

  Authors:Rico Beier, Elke Boschke, and Dirk LabuddeFrom:BioMed Research InternationalPeer-Reviewed

  Annual 20148,482 words Report 1410LAptamers are an interesting alternative to antibodies in pharmaceutics and biosensorics, because they are able to bind to a multitude of possible target molecules with high affinity. Therefore the process of finding...

• State of the art: hepatocellular carcinoma

  Author:Luigi BolondiFrom:Future Oncology (Vol. 10, Issue 15s) Peer-Reviewed

  Nov. 20143,758 words Report 2030LAuthor(s): Luigi Bolondi [*] KEYWORDS diagnosis; hepatocellular carcinoma; surveillance; treatment algorithms Hepatocellular carcinoma (HCC) is the most common primary liver cancer, mainly occurring in...

• Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies

  Authors:Ines de Paula Costa Monteiro, Pedro Madureira, Alessandro de Vasconscelos, Daniel Humberto Pozza, and Ramon Andrade de MelloFrom:Pharmacogenomics (Vol. 16, Issue 3) Peer-Reviewed

  Mar. 201511,133 words Report 1830LAuthor(s): Inês de Paula Costa Monteiro aff1 , Pedro Madureira aff2 aff3 , Alessandro de Vasconscelos aff4 aff5 , Daniel Humberto Pozza aff1 , Ramon Andrade de Mello [*] aff1 aff6 aff7 Keywords: antineoplastic...

• Expression of an engineered soluble coxsackievirus and adenovirus receptor by a dimeric AAV9 vector inhibits adenovirus infection in mice

  Authors:C. Roger, T. Pozzuto, R. Klopfleisch, J. Kurreck, S. Pinkert, and H. FechnerFrom:Gene Therapy (Vol. 22, Issue 6) Peer-Reviewed

  June 20157,092 words Report 1710LImmunosuppressed (IS) patients, such as recipients of hematopoietic stem cell transplantation, occasionally develop severe and fatal adenovirus (Ad) infections. Here, we analyzed the potential of a virus receptor trap...

• Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung

  Authors:Peter E Hall, James Spicer, and Sanjay PopatFrom:Future Oncology (Vol. 11, Issue 15) Peer-Reviewed

  Aug. 201513,700 words Report 1950LAuthor(s): Peter E Hall aff1 , James Spicer [*] aff1 aff2 , Sanjay Popat aff3 KEYWORDS afatinib; immune checkpoint; lung cancer; nivolumab; oncogenic drivers; pan-ErbB inhibitors; squamous cell carcinoma; targeted...

• Targeting survival pathway for future diabetic retinopathy therapeutics: XBP1 plays key role in retinal endothelial cell survival, retinal vascular degeneration

  Author:Vanessa CaceresFrom:Ophthalmology Times (Vol. 41, Issue 14) Peer-Reviewed

  Sept. 1, 2016469 words Article 1470LBUFFALO, NY :: THE TRANSCRIPTION factor X-box binding protein 1 (XBP1) may be a new therapeutic target to help prevent vascular damage in diabetic retinopathy, said Sarah X. Zhang, MD. Research led by Dr. Zhang...

• Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

  Authors:Nikolas Herold, Sean G Rudd, Linda Ljungblad, Kumar Sanjiv, Ida Hed Myrberg, Cynthia B J Paulin, et al.From:Nature Medicine (Vol. 23, Issue 2) Peer-Reviewed

  Feb. 201710,345 words Report 1650LAuthor(s): Nikolas Herold (corresponding author) [1]; Sean G Rudd [2]; Linda Ljungblad [1]; Kumar Sanjiv [2]; Ida Hed Myrberg [1]; Cynthia B J Paulin [2]; Yaser Heshmati [3]; Anna Hagenkort [2]; Juliane Kutzner [4];...